M Noonan, P Chervinsky, WW Busse, SC Weisberg, J Pinnas, BP de Boisblanc, H Boltansky, D Pearlman, L Repsher and D Kellerman
Allergy and Asthma Center, North Darmouth, Massachusetts, USA.

This study examined the ability of fluticasone propionate aerosol to reduce oral prednisone requirements in patients with severe asthma. Ninety-six patients dependent on oral prednisone were treated for 16 wk with placebo or fluticasone propionate aerosol (750 or 1,000 micrograms twice daily). Their dosage of oral prednisone was adjusted weekly according to predetermined criteria. A total of 69% and 88% of patients treated with fluticasone propionate 750 and 1,000 micrograms twice daily, respectively, compared with 3% of placebo-treated patients used no prednisone by the end of the study. In the fluticasone propionate groups, FEV1 and peak expiratory flow rates at the last evaluable visit/date improved and the number of night awakenings and symptomatic albuterol use declined relative to placebo values (p < 0.05). Patient- rated asthma symptoms improved in the groups receiving fluticasone propionate but not in the placebo group (p < 0.005). Fluticasone propionate aerosol was well-tolerated, and it improved some dimensions of health-related quality of life measured using a standard patient survey. Fluticasone propionate aerosol (750 or 1,000 micrograms twice daily) effectively and safely allowed most asthmatics dependent on oral corticosteroids to reduce or eliminate oral prednisone use while improving pulmonary function and quality of life.

This article has been cited by other articles:

				A. L. Fuhlbrigge, S. T. Weiss, K. M. Kuntz, A. D. Paltiel, and for the CAMP Research Group Forced Expiratory Volume in 1 Second Percentage Improves the Classification of Severity Among Children With Asthma Pediatrics, August 1, 2006; 118(2): e347 - e355. [Abstract] [Full Text] [PDF]

				Endpoints in asthma drug trials - what do they mean? DTB, March 1, 2006; 44(3): 21 - 24. [Abstract] [Full Text] [PDF]

				A.-S. Jang, J.-H. Lee, S. W. Park, Y. M. Lee, S. T. Uh, Y.-H. Kim, and C.-S. Park Factors Influencing the Responsiveness to Inhaled Glucocorticoids of Patients With Moderate-to-Severe Asthma Chest, September 1, 2005; 128(3): 1140 - 1145. [Abstract] [Full Text] [PDF]

				M Masoli, M Weatherall, S Holt, and R Beasley Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma Thorax, September 1, 2005; 60(9): 730 - 734. [Abstract] [Full Text] [PDF]

				S. Wenzel Severe Asthma in Adults Am. J. Respir. Crit. Care Med., July 15, 2005; 172(2): 149 - 160. [Abstract] [Full Text] [PDF]

				J. F. Donohue and J. A. Ohar Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 152 - 160. [Abstract] [Full Text] [PDF]

				G. L. Colice Categorizing Asthma Severity: An Overview of National Guidelines Clin. Med. Res., August 1, 2004; 2(3): 155 - 163. [Abstract] [Full Text] [PDF]

				D. D. Sin, J. Man, H. Sharpe, W. Q. Gan, and S. F. P. Man Pharmacological Management to Reduce Exacerbations in Adults With Asthma: A Systematic Review and Meta-analysis JAMA, July 21, 2004; 292(3): 367 - 376. [Abstract] [Full Text] [PDF]

				S. O'Sullivan, L. Cormican, M. Murphy, L. W. Poulter, and C. M. Burke Effects of Varying Doses of Fluticasone Propionate on the Physiology and Bronchial Wall Immunopathology in Mild-to-Moderate Asthma Chest, December 1, 2002; 122(6): 1966 - 1972. [Abstract] [Full Text] [PDF]

				R J Meijer, D S Postma, and H A M Kerstjens Conventional RIA underestimates cortisol suppression in the presence of prednisolone Thorax, April 1, 2002; 57(4): 374 - 374. [Full Text] [PDF]

				G. VAN DEN BOOM, M. P. M. H. RUTTEN-VAN MOLKEN, J. MOLEMA, P. R. S. TIRIMANNA, C. VAN WEEL, and C. P. VAN SCHAYCK The Cost Effectiveness of Early Treatment with Fluticasone Propionate 250 {micro}g Twice a Day in Subjects with Obstructive Airway Disease . Results of the DIMCA Program Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2057 - 2066. [Abstract] [Full Text] [PDF]

				B. J. Lipworth, R. A. Nathan, and R. ZuWallack Fluticasone and Cortisol Measurements Chest, March 1, 2001; 119(3): 984 - 985. [Full Text] [PDF]

				L FABBRI and R MELARA Systemic effects of inhaled corticosteroids are milder in asthmatic patients than in normal subjects Thorax, March 1, 2001; 56(3): 165 - 166. [Full Text]

				S. SPENCER, P. M. A. CALVERLEY, P. SHERWOOD BURGE, and P. W. JONES Health Status Deterioration in Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 122 - 128. [Abstract] [Full Text]

				S. Wenzel Proceedings of the ATS Workshop on Refractory Asthma . Current Understanding, Recommendations, and Unanswered Questions Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2341 - 2351. [Full Text]

				R. A. Nathan, J. T. C. Li, A. Finn, R. Jones, J. E. Payne, J. P. Wolford, and S. M. Harding A Dose-Ranging Study of Fluticasone Propionate Administered Once Daily via Multidose Powder Inhaler to Patients With Moderate Asthma Chest, August 1, 2000; 118(2): 296 - 302. [Abstract] [Full Text] [PDF]

				J. W HONOUR;, R. J MEIJER, H. A M KERSTJENS, and D. S POSTMA Fluticasone in asthma Thorax, August 1, 2000; 55(8): 722c - 722. [Full Text]

				J. BOUSQUET, P. K. JEFFERY, W. W. BUSSE, M. JOHNSON, and A. M. VIGNOLA Asthma . From Bronchoconstriction to Airways Inflammation and Remodeling Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1720 - 1745. [Full Text]

				B. J. Lipworth Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis Arch Intern Med, May 10, 1999; 159(9): 941 - 955. [Abstract] [Full Text] [PDF]

				N. K. LEIDY, K. S. CHAN, and C. COUGHLIN Is the Asthma Quality of Life Questionnaire a Useful Measure for Low-income Asthmatics? Am. J. Respir. Crit. Care Med., October 1, 1998; 158(4): 1082 - 1090. [Abstract] [Full Text] [PDF]

				J. L Faul, C. T Leonard, C. M Burke, V. J Tormey, and L. W Poulter Fluticasone propionate induced alterations to lung function and the immunopathology of asthma over time Thorax, September 1, 1998; 53(9): 753 - 761. [Abstract] [Full Text]

				E. M. Andresen, B. M. Rothenberg, R. Panzer, P. Katz, and M. P. Mcdermott Selecting a Generic Measure of Health-Related Quality of Life for Use among Older Adults: A Comparison of Candidate Instruments Eval Health Prof, June 1, 1998; 21(2): 244 - 264. [Abstract] [PDF]

				P. J. BARNES, S. PEDERSEN, and W. W. BUSSE Efficacy and Safety of Inhaled Corticosteroids . New Developments Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): S1 - 53. [Full Text] [PDF]

				J. R. CURTIS, D. P. MARTIN, and T. R. MARTIN Patient-assessed Health Outcomes in Chronic Lung Disease . What are They, How Do They Help Us, and Where Do We Go From Here? Am. J. Respir. Crit. Care Med., October 1, 1997; 156(4): 1032 - 1039. [Full Text] [PDF]

				M. LAWRENCE, J. WOLFE, D. R. WEBB, P. CHERVINSKY, D. KELLERMAN, J. P. SCHAUMBERG, and T. SHAH Efficacy of Inhaled Fluticasone Propionate in Asthma Results from Topical and Not from Systemic Activity Am. J. Respir. Crit. Care Med., September 1, 1997; 156(3): 744 - 751. [Abstract] [Full Text] [PDF]